Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Coherus Oncology, Inc. - Common Stock
(NQ:
CHRS
)
2.350
+0.135 (+6.09%)
Streaming Delayed Price
Updated: 3:34 PM EST, Jan 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Coherus Oncology, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Why Coherus BioSciences Stock Popped Today
↗
October 05, 2023
Coherus resubmitted a license application for a key product today. Here's what investors need to know.
Via
The Motley Fool
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
October 05, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
October 04, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
October 02, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
4 Analysts Have This to Say About Coherus BioSciences
↗
September 26, 2023
Via
Benzinga
Why Coherus BioSciences Stock Popped Today
↗
August 03, 2023
The immuno-oncology leader delivered a strong second quarter.
Via
The Motley Fool
Analyst Ratings for Coherus BioSciences
↗
August 03, 2023
Via
Benzinga
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 27, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
↗
September 25, 2023
The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of...
Via
Benzinga
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
September 25, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Earnings Preview For Coherus BioSciences
↗
August 01, 2023
Via
Benzinga
10 Analysts Have This to Say About Coherus BioSciences
↗
July 14, 2023
Via
Benzinga
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
September 25, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Via
Benzinga
Coherus BioSciences Announces New Employment Inducement Grants
September 22, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Completes Surface Oncology Acquisition
September 08, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus BioSciences Stock Was Plunging This Week
↗
September 08, 2023
The "index effect" is real, although typically not long-lasting.
Via
The Motley Fool
Airbnb, Blackstone Rise On News They'll Join S&P 500 Index
↗
September 02, 2023
ABNB and BX will join Sept. 18 as part of a quarterly rebalancing.
Via
Investor's Business Daily
Topics
Stocks
Coherus BioSciences to Participate at Upcoming September Investor Conferences
September 01, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
August 31, 2023
Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting
From
Surface Oncology, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
August 22, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Cummins Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
August 03, 2023
Gainers Bluejay Diagnostics, Inc. (NASDAQ: BJDX) shares jumped 75% to $9.60.
Via
Benzinga
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
↗
August 03, 2023
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. Traeger, Inc. (NYSE: COOK) shares jumped 43.2% to $5.90...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
August 02, 2023
Via
Benzinga
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
August 02, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
July 26, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
↗
July 24, 2023
Via
Benzinga
Coherus BioSciences Announces New Employment Inducement Grants
July 21, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
July 20, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Mark Cuban's Pharmacy Company Lands Deal With Top 10 US Retailer: Here Are The Details
↗
July 19, 2023
Since launching the Mark Cuban Cost Plus Drug Company in 2022, entrepreneur and NBA team owner Mark Cuban has been on a mission to lower the cost of medicines for consumers.
Via
Benzinga
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
July 13, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.